Home Diabetes Investigator Profile: Paresh Dandona Influences EU Dapagliflozin Approval

Investigator Profile: Paresh Dandona Influences EU Dapagliflozin Approval

168
0
Investigator

Paresh Dandona, SUNY Distinguished Professor of medicine and chief of endocrinology, diabetes and metabolism, has conducted pioneering research playing a key role in the European Commission’s decision to approve dapagliflozin for patients with type 1 diabetes.

Professional Summary

Vascular cell reactivity encompassing platelet function, endothelial function, monocyte/macrophage function and the interactions between them (adhesion molecules viz lCAM, VCAM, P-selectin, L-selectin, E-selectin, etc.). Reactive Oxygen Species (ROS) in diabetes, atherosclerosis, hypertension, aging, infection, etc. and a consequential damage to lipids, proteins and DNA. Regulation of aromatase, the effect of estrogen on estrogen receptor, androgen receptor and glucocortico receptor (elucidationi of pre- and post-receptor mechanisms in menopause, etc.). Venous reactivity with measurements of venous diameter and flow velocity and the effect of various drugs in NIDDM, IDDM, and IGT. Genetic regulation of aromatase and estrogen receptor. The role of nitric oxide in vascular reactivity, vis-a-vis various complications of diabetes and other factors involved with vascular reactivity. Effects of endotoxin on adhesion molecules, PAF, platelets, ROS and procalcitonin.

Education and Training

  • Fellowship, American College of Endocrinology (2004)
  • Fellowship, American College of Cardiology (1996)
  • Fellowship, American College of Physicians (1995)
  • Fellowship, Royal College of Physicians (U.K.) (1988)
  • PhD, Oxford University (1975)
  • MBBS, Medicine, All India Institute of Medical Sciences (1965)
  • BS, Chemistry, Allahabad University (1960)

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.